SR9011
CAS: 1379686-29-9
Rif. 3D-EFC68629
| 10mg | Prezzo su richiesta | ||
| 25mg | Prezzo su richiesta | ||
| 50mg | Prezzo su richiesta |
Informazioni sul prodotto
- 3-[[(4-Chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide
- 3-[[[(4-Chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-N-pentyl-1-pyrrolidinecarboxamide
- 1-Pyrrolidinecarboxamide, 3-[[[(4-chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-N-pentyl-
- SR 9011
SR9011 is a small-molecule drug that has been shown to have anti-cancer effects. It is currently undergoing clinical trials for the treatment of cancer, including glioblastoma (brain cancer) and non-small cell lung cancer. SR9011 inhibits the activation of microglia cells in the brain, which are associated with neurological disorders such as Alzheimer's disease and Parkinson's disease. This drug also reduces skin inflammation and can be used to treat inflammatory diseases such as Crohn's disease or ulcerative colitis. SR9011 can also be used to treat metabolic disorders, such as type 2 diabetes or obesity. The mechanism of action for SR9011 is not fully understood, but it has been shown to activate autophagy in human liver cells and beta-cells in the pancreas.
SR9011 was originally developed by Sirtris Pharmaceuticals under the code name "SR9009."
Proprietà chimiche
Richiesta tecnica su: 3D-EFC68629 SR9011
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
